Interpace Biosciences Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Interpace Biosciences.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Healthcare kazanç büyümesi	20.1%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Recent updates

Interspace Biosciences trades high, appoints new finance chief

Feb 04

Interpace signs licensing agreement for monoclonal antibody platform Das-1

Feb 01

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Interpace Biosciences yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

OTCPK:IDXG - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2024	42	3	3	4	N/A
3/31/2024	41	1	2	3	N/A
12/31/2023	40	1	3	4	N/A
9/30/2023	38	-1	2	2	N/A
6/30/2023	37	-2	-2	-2	N/A
3/31/2023	34	-4	-6	-5	N/A
12/31/2022	32	-6	-8	-8	N/A
9/30/2022	33	-6	-9	-9	N/A
6/30/2022	32	-6	-6	-6	N/A
3/31/2022	31	-4	-5	-5	N/A
12/31/2021	33	-7	-9	-9	N/A
9/30/2021	34	-13	-10	-9	N/A
6/30/2021	34	-18	-15	-14	N/A
3/31/2021	33	-24	-13	-12	N/A
12/31/2020	32	-29	-16	-14	N/A
9/30/2020	27	-32	-20	-19	N/A
6/30/2020	26	-33	-19	-18	N/A
3/31/2020	27	-33	-23	-23	N/A
12/31/2019	24	-27	-19	-19	N/A
9/30/2019	26	-20	-15	-14	N/A
6/30/2019	24	-16	-12	-11	N/A
3/31/2019	23	-12	-10	-9	N/A
12/31/2018	22	-12	-9	-9	N/A
9/30/2018	20	-13	-10	-9	N/A
6/30/2018	19	-13	-12	-12	N/A
3/31/2018	17	-18	N/A	-14	N/A
12/31/2017	16	-13	N/A	-15	N/A
9/30/2017	15	-1	N/A	-14	N/A
6/30/2017	14	-5	N/A	-11	N/A
3/31/2017	14	-3	N/A	-8	N/A
12/31/2016	13	-8	N/A	-8	N/A
9/30/2016	13	-23	N/A	-13	N/A
6/30/2016	12	-23	N/A	-17	N/A
3/31/2016	10	-28	N/A	-18	N/A
12/31/2015	9	-31	N/A	-20	N/A
9/30/2015	-83	-31	N/A	-22	N/A
6/30/2015	-57	-27	N/A	-16	N/A
3/31/2015	-28	-20	N/A	-16	N/A
12/31/2014	1	-13	N/A	-16	N/A
9/30/2014	123	-6	N/A	-12	N/A
6/30/2014	129	-5	N/A	-11	N/A
3/31/2014	135	-4	N/A	-11	N/A
12/31/2013	147	-2	N/A	-4	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if IDXG's forecast earnings growth is above the savings rate (2.5%).

Kazançlar ve Piyasa: Insufficient data to determine if IDXG's earnings are forecast to grow faster than the US market

Yüksek Büyüme Kazançları: Insufficient data to determine if IDXG's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if IDXG's revenue is forecast to grow faster than the US market.

Yüksek Büyüme Geliri: Insufficient data to determine if IDXG's revenue is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if IDXG's Return on Equity is forecast to be high in 3 years time

Interpace Biosciences Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Interpace Biosciences, Inc. Provides Revenue Guidance for the Full Year 2021

Interpace Biosciences, Inc. Provides Revenue Guidance Second Quarter of Fiscal 2021

Interpace Biosciences, Inc. Provides Full Year Revenue Guidance for 2021

Recent updates

Interpace Biosciences, Inc. announced that it has received $47 million in funding

Interpace Biosciences, Inc., Annual General Meeting, Nov 12, 2024

Interpace Diagnostics Announces New Data Analyzing Imbalance of Short Tandem Repeat Alleles for Pancreatic Cancer Detection Published as an ASCO 2024 Abstract

Robert Gorman Provides Notice to Interpace Biosciences, Inc. of His Resignation as A Director and as Chairman of the Board, Including as A Member of the Board’s Regulatory Compliance Committee

Interpace Biosciences, Inc. Announces Resignation of Edward Chan as Class II Director

Interpace Biosciences, Inc., Annual General Meeting, Nov 14, 2023

Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Chief Financial Officer

Interpace Biosciences, Inc. Expects to Stop Offering Pancragen Test Due to CMS Decision to End Reimbursement as of July 17, 2023

Interpace Biosciences, Inc., Annual General Meeting, Nov 10, 2022

Interpace Biosciences, Inc. Announces New Clinical Validation Data

Flagship Biosciences, Inc. completed the acquisition of Interpace Pharma Solutions from Interpace Biosciences, Inc. (OTCPK:IDXG).

Interpace Biosciences, Inc. Announces New Clinical Validation Data for Thyroid Cancer Test Platform Published Online Within Thyroid®, the Leading Peer-Reviewed Journal for Original Research on Thyroid Cancer

Interpace Biosciences, Inc Announces Update of Previously Announced CMS Billing Policy Impacting its Thyroid Tests

Interpace Biosciences Announces Appointment of Vijay Aggarwa as New Director to the Board of Directors

Interpace Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $27.930299 million.

Interpace Biosciences, Inc. Provides Revenue Guidance for the Full Year 2021

Interpace Biosciences, Inc. Provides Revenue Guidance Second Quarter of Fiscal 2021

Interpace Biosciences, Inc. announced delayed annual 10-K filing

Interpace Biosciences, Inc. Provides Full Year Revenue Guidance for 2021

DiamiR, LLC entered into a definitive agreement to acquire a CLIA certified laboratory in New Haven of Interpace Biosciences, Inc. (OTCPK:IDXG).

Interpace Biosciences, Inc. Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois

Interpace Biosciences to Be Delisted from Nasdaq and to Commence Trading on OTCQX

Interpace Biosciences Announces Impending Delisting from Nasdaq

Interpace Biosciences, Inc. Announces CFO Changes

Interpace Biosciences, Inc. Announces Executive Changes

Interspace Biosciences trades high, appoints new finance chief

Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital

Interpace signs licensing agreement for monoclonal antibody platform Das-1

Interpace Biosciences, Inc. Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Florida

Interpace Biosciences, Inc. to Report Q3, 2020 Results on Jan 21, 2021

Interpace Biosciences, Inc. Announces CEO Changes

Interpace Biosciences Receives Nasdaq Deficiency Notice

Interpace Biosciences, Inc. announced delayed 10-Q filing

Interpace Biosciences, Inc. Announces Results of Seminal Clinical Validation Study for Thyroid Assays

Interpace Biosciences Receives Notice from Listing Qualifications Staff on Nasdaq

Interpace Biosciences, Inc. announced delayed 10-Q filing

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin